Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

Glow Blend

RecoveryPreclinical

Also known as: Glow, GHK-Cu/BPC/TB

GHK-Cu + BPC-157 + TB-500 blend for skin and recovery.

Lowest price per mg

$1.50/mg$104.99 for 70mg

at ResearchChemHQ ·

Buy at RC

Half-life: Varies by component - the blend has no single half-life

Last reviewed: Oct 3, 2026

Overview

At A Glance

Mechanism

Glow Blend is a fixed combination of three research peptides, so its proposed effects are simply the sum of what each component does on its own - there is no unique "blend" mechanism, and no pharmacology study has ever been run on the three together. Each part is covered in dep…

Half-Life

Varies by component - the blend has no single half-life. BPC-157 and the TB-500 (thymosin beta-4) fragment are small peptides cleared over hours; GHK-Cu is a short-lived tripeptide-copper complex. Community dosing frequency is driven by empirical practice, not by measured pharmacokinetics of the blend.

Dosing

GHK-Cu once daily; BPC-157 once to twice daily; TB-500 twice weekly during the loading phase, then every 1-2 weeks for maintenance.

Dose Range

Blend - stated per component: GHK-Cu 1000-2000 mcg/day; BPC-157 250-500 mcg/dose; TB-500 2000-2500 mcg/dose. No validated dose exists for the combination (Research Use Only).

Potential Benefits

Improved skin firmness and elasticity - GHK-Cu raised collagen and elastin and improved aged-skin firmness in controlled cosmetic studies [PMID:18644225]Reduced appearance of fine lines and photodamage (GHK-Cu cosmetic data) [PMID:18644225]Support for wound and connective-tissue repair - GHK-Cu and BPC-157 accelerated healing in animal models [PMID:8836453][PMID:30915550]Angiogenesis / improved local blood-vessel formation - a shared mechanism of BPC-157 and the thymosin beta-4 fragment in TB-500 [PMID:20388964][PMID:14500546]Faster recovery from tendon, ligament and muscle strain (BPC-157 preclinical data) [PMID:30915550]Anti-inflammatory and antioxidant support during recovery (GHK-Cu and thymosin beta-4) [PMID:18644225][PMID:27450738]Reported skin 'glow' and quicker soft-tissue recovery - community/anecdotal only, not clinically verified for the blend

Safety Notes

Common

Injection-site redness, swelling, itching, bruising, transient painmild skin sensitivity

Mechanism of Action

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide. In cosmetic-science and wound-healing literature it acts as a tissue-remodeling signal: it is chemotactic for repair cells, has anti-inflammatory and antioxidant activity, and up-regulates synthesis of collagen, elastin and several growth factors (VEGF, FGF-2, NGF) while modulating matrix metalloproteinases. Controlled studies on aged human skin reported improved firmness and elasticity and reduced fine lines [PMID:18644225]; fibroblast and animal wound work showed increased collagen expression [PMID:8836453].

BPC-157 is a synthetic stable gastric pentadecapeptide. Its best-characterized action in rodent models is angiomodulation - it up-regulates VEGF and promotes organized new-vessel formation, which is tied to faster tendon, ligament and muscle healing [PMID:20388964][PMID:30915550]. All of this evidence is preclinical; efficacy has not been confirmed in humans.

TB-500 is the synthetic, N-acetylated form of LKKTETQ - the actin-binding "active region" of the natural protein thymosin beta-4 [PMID:23084823]. That short motif carries much of thymosin beta-4's angiogenic and cell-migration activity [PMID:14500546], and full-length thymosin beta-4 accelerated dermal wound repair and reduced inflammation in animal models and early-phase human ulcer trials [PMID:27450738].

Community rationale for combining them: GHK-Cu supplies the collagen/elastin cosmetic signal while BPC-157 and TB-500 are added for angiogenesis and connective-tissue recovery. This synergy is a plausibility argument built from the component mechanisms, not something demonstrated for the finished blend. Research Use Only.

What to Expect

•Skin goals (from GHK-Cu) develop slowly - cosmetic studies ran over weeks to a couple of months before firmness/elasticity changes were noted; do not expect overnight results

•Recovery goals (from BPC-157 and TB-500) are reported anecdotally over a multi-week cycle, not after a single dose

•The most common day-to-day experience is minor injection-site reactions (redness, sting, occasional bruising)

•No validated timeline exists for the blend itself - these expectations are extrapolated from the individual components and user reports

Individual responses vary. Timeline based on commonly reported research observations.

Chemical Information

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Blend

Molecular Mass

Not yet available

Dosing & Protocols

Dosing Summary

Dose

Blend - stated per component: GHK-Cu 1000-2000 mcg/day; BPC-157 250-500 mcg/dose; TB-500 2000-2500 mcg/dose. No validated dose exists for the combination (Research Use Only).

Route

Subcutaneous injection after reconstitution with bacteriostatic water; GHK-Cu is also used topically for skin-only goals

Frequency

GHK-Cu once daily; BPC-157 once to twice daily; TB-500 twice weekly during the loading phase, then every 1-2 weeks for maintenance.

Duration

Community cycles typically run 4-8 weeks followed by an off period of several weeks. No evidence supports continuous use.

Research Use Only. No dosing has been validated for the blend - ranges are extrapolated from each component's community use.

Unlock the dosing protocols

Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

Route, how often and how long
Beginner, intermediate and advanced protocols
Additional dosage notes

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in

Research

PubMed Results

Key Research Findings

There are no clinical studies on Glow Blend. The combination has never been tested as a blend in humans or animals. The following is the evidence for its individual components - all of which should be read as Research Use Only.

GHK-Cu: A body of cosmetic and wound-healing research describes GHK-Cu as a tissue-remodeling peptide that increases collagen and elastin and, in controlled studies on aged skin, improves firmness and elasticity and reduces fine lines [PMID:18644225]. Fibroblast and animal studies show increased collagen expression and effects on skin repair [PMID:8836453].

BPC-157: Evidence is entirely preclinical (mostly rodent). Studies report accelerated tendon, ligament and muscle healing, attributed to angiomodulation and VEGF up-regulation [PMID:20388964][PMID:30915550]. No human efficacy trials exist.

TB-500 / thymosin beta-4: TB-500 is the synthetic active fragment (N-acetyl-LKKTETQ) of thymosin beta-4 [PMID:23084823]. That fragment carries the peptide's angiogenic, actin-binding activity [PMID:14500546], and full-length thymosin beta-4 accelerated dermal healing and reduced inflammation in animal models and early-phase human ulcer trials [PMID:27450738].

Bottom line: the component data are promising but largely preclinical or early-phase, none of it validates the finished blend, and none of these peptides is an approved therapeutic. According to PubMed.

Safety & Side Effects

Most reported effects are local: injection-site redness, swelling, itching, bruising or transient pain, plus mild skin sensitivity. GHK-Cu injections can sting, and with prolonged high-dose systemic use there is a theoretical concern for copper accumulation. BPC-157 and TB-500 are generally described as well tolerated in animal studies and community use, but neither has undergone the long-term human safety testing that would define a real side-effect profile - unknown long-term risk is the honest bottom line. Rare: allergic/hypersensitivity reaction to any component. Because TB-500 and BPC-157 are angiogenic (they promote blood-vessel growth), there is a theoretical caution around active or undiagnosed cancer. Any report specific to this blend is anecdotal.

Unlock the research summary

Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

A summary of the key research
Safety and side effects
A link to the PubMed results

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in

Interactions

Interaction Matrix

Contraindications

Do not use with a known allergy to any component (GHK-Cu, BPC-157 or TB-500) or to copper. Avoid injecting into active skin infections or broken/inflamed skin. Not for use in pregnancy or breastfeeding. Because two of the three components promote angiogenesis, avoid with active cancer or a personal history of cancer, or speak with a physician first. Use caution with Wilson's disease or other copper-metabolism disorders due to the copper in GHK-Cu. This is a Research Use Only product, not approved for human therapeutic use; anyone considering it should consult a qualified clinician.

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

Best Price

$99.99

up to $199.99

Best $/mg

$1.4999

Vendors

Listings

vial, pen

Form

Sort

Vendor	Product	Form	Qty	Price	$/mg	Coupon
ResearchChemHQ 100 🇺🇸US	Glow Blend 70mg	vial	1 vial● In Stock	$104.99VALUE	$1.50
Disguised Alpha 50 🇺🇸US🇪🇺EU🇬🇧UK	GLOW (GHK-Cu / BPC-157 / TB-500)	vial	1 vial● In Stock	$99.99BEST	—	—
Disguised Alpha 50 🇺🇸US🇪🇺EU🇬🇧UK	GLOW Pen (GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg)	pen	1 pen (50 + 10 + 10 mg)● In Stock	$199.99	$2.86	—
Optimum Formula 100 🇺🇸US	Glow Blend 70mg	vial	1 vial● In Stock	$104.99	$1.50

Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Glow Blend.

Current low

$99.99

current listings

7-day low

—

not enough history yet

30-day low

—

not enough history yet

30-day change

—

not enough history yet

Tracking since Mar 13, 2026 · 3 data points

Price History

2 data points

Vendors Selling Glow Blend

How we score these vendors

Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.

View Scorecard

Related Compounds

View All

ARA-290

RecoveryPhase 2

ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.

t½ ~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days) 1 mg - 4 mg subcutaneous daily

52 PubMedView Profile

BPC-157/TB-500 Blend

RecoveryPreclinical

Combined healing peptide blend.

t½ BPC-157: short - under ~30 min in animal PK studies (rats/dogs); no human PK data. TB-500 (thymosin beta-4): active fragment ~30 min, though tissue effects are prolonged. Dosed per component (a fixed daily blend over-doses TB-500 - see notes). BPC-157: 250-500 mcg once daily SUBQ. TB-500 (thymosin beta-4): 2-2.5 mg twice weekly during a 4-6 week loading phase, then 2-2.5 mg once weekly for maintenance (~5 mg/week during loading). If a pre-blended fixed-ratio daily vial is used, its TB-500 fraction should be ~250-350 mcg per injection so the weekly TB-500 total stays near ~5 mg.

PreclinicalView Profile

Bronchogen

RecoveryPreclinical

Bronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.

t½ Not established (no published human pharmacokinetic data; rapid enzymatic hydrolysis within minutes is expected for a tetrapeptide of this class) 20 mg oral capsule once daily, 10-day cycles

7 PubMedView Profile

CAG

RecoveryNot a defined single compound

CAG is not a standardized research-peptide designation.

t½ Unknown

PreclinicalView Profile

Cardiogen

RecoveryPreclinical

Cardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.

t½ Not characterized in humans. As a short linear tetrapeptide (Ala-Glu-Asp-Arg), Cardiogen is expected to undergo rapid enzymatic hydrolysis to its constituent amino acids; no validated modern pharmacokinetic half-life has been published. 20 mg oral once daily x10 days, or 2-5 mg SC daily x10 days; 60-90 day washout

9 PubMedView Profile

Cartalax

RecoveryPreclinical

Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.

t½ No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured. 20 mg oral/sublingual once daily for 10 days; 60-90 day washout

6 PubMedView Profile

View Full Dosage Guide →

Protocols, calculator & safety for Glow Blend

All Posts

Why Bob Built ResearchChemHQ: A Founder Interview (2026)

A short interview with Bob, founder of ResearchChemHQ, a peptide vendor since 2020. He covers why he started, how every batch gets HPLC, mass spec, and endotoxin testing at an ISO-certified third-party lab, why domestic shipping matters, and what code REDDIT actually unlocks at checkout (10% off, stackable with their volume tiers up to 40%).

5/8/2026

Lowest Price per mg

⚗️

ResearchChemHQ

$104.99($1.50/mg)

3 vendors · 4 listings

Research Score

0 PubMed results

Quality Indicators

Data Completeness

88%

Description

Mechanism of Action

Chemical Data

Dosing Protocols

Safety Profile

PubMed Results

Interactions

Vendor Listings

COA Verification

Verified COAs

Vendors w/ COA

High verification rate (83%)

Latest test: 3/1/2026

Quick Facts

Half-Life

Trial Phase

Preclinical

Safety Profile

Common Side Effects

• Injection-site redness, swelling, itching, bruising, transient pain
• mild skin sensitivity

Research Disclaimer

This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

Frequently Asked Questions

Does Glow Blend have its own clinical trials?

No. There are no clinical trials - or even formal preclinical studies - on the GHK-Cu + BPC-157 + TB-500 combination. Every piece of evidence on this page comes from studies of the individual components, and the rationale for combining them is anecdotal. Treat it as Research Use Only.

What is each ingredient for?

GHK-Cu is a copper tripeptide studied for collagen/elastin synthesis and skin firmness [PMID:18644225]. BPC-157 is a pentadecapeptide studied in animals for tendon, ligament and muscle healing via angiogenesis [PMID:30915550]. TB-500 is the synthetic active fragment of thymosin beta-4, studied for angiogenesis and wound repair [PMID:27450738]. See GHK-Cu, BPC-157 and TB-500.

Is TB-500 the same as thymosin beta-4?

Not exactly. TB-500 is a synthetic, N-acetylated version of LKKTETQ - the actin-binding 'active region' of the full thymosin beta-4 protein [PMID:23084823]. That short motif carries much of thymosin beta-4's angiogenic activity [PMID:14500546], but it is a fragment, not the whole protein.

How is Glow Blend dosed?

Community protocols dose each component separately: GHK-Cu ~1-2 mg/day, BPC-157 ~250-500 mcg per dose, and TB-500 ~2-2.5 mg twice weekly during a loading phase. There is no studied ratio for the blend, so these are extrapolations, not validated doses.

Is it safe?

The components are generally described as well tolerated in short-term animal and early human studies, but none has long-term human safety data and the blend itself has none at all. Known issues are mostly injection-site reactions; the honest position is that long-term risk is unknown. It is not approved for human use.

Can I just use topical GHK-Cu instead?

If your only goal is skin appearance, topical GHK-Cu cosmetic formulations are the most evidence-backed part of this stack [PMID:18644225] and avoid injections entirely. The injectable blend is aimed at people also seeking the systemic soft-tissue recovery attributed to BPC-157 and TB-500.